TREMFYA® is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn's disease, inclusive of those who are biologic-naïve and ...

"Treatment with TREMFYA resulted in significant improvement in the chronic symptoms of ulcerative colitis, and importantly, normalization in the endoscopic appearance of the intestinal lining," said ...

First-of-its-kind Phase 3b study shows TREMFYA ® achieved statistical significance across all primary and secondary endpoints in low body surface area psoriasis with special site involvement Johnson & ...

People with psoriatic arthritis (PsA) often take medicines to help manage their condition and improve their symptoms. Some of these medicines work directly on the body's immune system and help to ...

Tremfya is a biologic medication administered via injections into a vein or under the skin to treat plaque psoriasis. It works by blocking interleukin-23, a protein involved in the overactive immune ...

The FDA has approved Tremfya (guselkumab; Janssen) One-Press, a single-dose patient-controlled injector for the treatment of moderate-to-severe plaque psoriasis in adults. The Food and Drug ...

Endo International’s Qwo (collagenase clostridium histolyticum-aaes [CCH] injection) has been approved as the first injectable therapy for moderate to severe cellulite in adult women. The approval was ...